1	Carnosine supplementation improves glucose control in adults with pre-diabetes and
2	type 2 diabetes: a randomised controlled trial
3	
4 5	Rohit Hariharan ¹ , James Cameron ^{1,2} , Kirthi Menon ¹ , Jakub Mesinovic ^{1,3} , Paul Jansons ^{1,3} , David Scott ^{1,3} , Zhong X Lu ^{1,4} , Maximilian de Courten ⁵ , Jack Feehan ^{5*} , Barbora de Courten ^{1,6*}
6	¹ Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton
7	VIC, Australia
8	² Monash Cardiovascular Research Centre, Monash Heart, Monash Health, Clayton VIC Australia.
9	³ Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences,
10	Deakin University, Geelong VIC, Australia
11	⁴ Monash Health Pathology, Clayton, VIC, Australia
12	⁵ Mitchell Institute for Health and Education Policy, Victoria University, Melbourne VIC, Australia
13	⁵ Institute for Health and Sport, Victoria University, Footscray, VIC, Australia
14	⁶ School of Health and Biomedical Sciences, RMIT, Bundoora
15	Corresponding author:
16	Professor Barbora de Courten, MD PhD MPH FRACP ExecMBA
17	School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia
18	Telephone: +61 3 9925 6474
19	Email: barbora.decourten@rmit.edu.au
20	
21	Words: 3435
21	Figures 1
22	rigures: i

23 Tables: 3 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 Abstract:

25 Type 2 diabetes (T2DM) is a major cause of morbidity and mortality globally. Carnosine, a naturally occurring dipeptide, has anti-inflammatory, antioxidant, and anti-glycating effects, with preliminary 26 27 evidence suggesting it may improve important chronic disease risk factors in adults with cardiometabolic conditions. In this randomized controlled trial, 43 adults (30%F) living with 28 prediabetes or T2DM consumed carnosine (2 grams) or a matching placebo daily for 14 weeks to 29 evaluate its effect on glucose metabolism assessed via 2 hr, 75g oral glucose tolerance test. Secondary 30 outcomes included body composition analysis by dual energy x-ray absorptiometry (DEXA), calf 31 muscle density by pQCT and anthropometry. Carnosine supplementation decreased blood glucose at 90 32 minutes (-1.31mmol/L; p=0.02) and 120 minutes (-1.60mmol/L, p=0.02) and total glucose area under 33 34 the curve (-3.30mmol/L; p=0.04) following an oral glucose tolerance test. There were no additional changes in secondary outcomes. The carnosine group results remained significant before and after 35 adjustment for age, sex, and change in weight (all>0.05), and in further sensitivity analyses accounting 36 for missing data. There were no significant changes in insulin levels. Likely mechanisms may include 37 38 changes to hepatic glucose output explaining the observed reduction in blood glucose without changes in insulin secretion following carnosine supplementation. This study provides preliminary support for 39 40 larger trials evaluating carnosine as a potential treatment for prediabetes and the early stages of T2DM.

42 Introduction:

Type 2 diabetes (T2DM) continues to place an immense burden on healthcare systems globally¹. The 43 World Health Organization (WHO) estimates that over the last 40 years, the number of people with 44 diabetes has increased from 108 million to 451 million and will increase to 693 million by 2045^{1,2}. This 45 rapid increase has cemented diabetes as a leading cause of mortality³ and a major contributor to burden 46 of disease globally⁴ and a leading cause of mortality³. Diabetes increases the risk of all-cause mortality 47 by 2-3 times⁵ and contributes to as much as 80% of all premature deaths caused by non-communicable 48 disease⁵. It is also an immense economic burden, with \$760 billion USD spent globally on diabetes and 49 its complications in 2019 alone⁵. This is projected to rise to \$825 billion by 2030 and \$845 billion by 50 51 2045^5 .

52 Due to its significant healthcare and societal burden, effective management of T2DM is critical. The principal aims of management of T2DM are to lower and stabilize blood glucose levels, which 53 54 decreases the incidence and severity of microvascular and macrovascular complications, improves quality of life, and reduces mortality⁶. More than 120 million people with diabetes worldwide are 55 prescribed metformin as their main therapy, making it the most broadly used glucose-lowering 56 57 medication globally⁷. Other medications used include dipeptidyl peptidase 4 (DPP4) inhibitors, sodiumglucose co-transporter 2 (SGLT2) inhibitors, sulfonylureas, and the glucagon like peptide (GLP-1) 58 59 receptor agonists⁸. These medications are hampered by adverse events, including hypoglycemic episodes, with resultant sequelae, and some cannot be prescribed in patients with common diabetic 60 comorbidities, such as severe chronic renal disease⁹. This makes the identification of safe and effective 61 62 means to better control glucose an ongoing priority for researchers.

Carnosine, anserine, and ophidine/balenine, a group of naturally occurring histidine containing
dipeptides (HCD), are present in large amounts in the skeletal muscle and brain of mammals¹⁰⁻¹⁴.
Carnosine has several physiological activities in humans, being a potent antioxidant, and metal chelator
as well as anti-inflammatory, and anti-glycating effects^{14,15}. Carnosine supplementation has been shown
to improve glycemic control and insulin levels in adults with prediabetes and diabetes¹⁶⁻¹⁹, and it also

has a positive effect on the blood lipidome by maintaining levels of trihexosylceramide and
phosphatidylcholine and free cholesterol levels^{17,20-22}.

70 However, studies investigating the role of carnosine in glucose metabolism are limited by small 71 numbers of participants, frequently treated concomitantly with a variety of glucose-lowering 72 medications as well as a lack of randomized placebo-controlled studies of participants with overweight or obese. Therefore, our aim was to evaluate the effect of a 14-week carnosine supplement regimen for 73 T2DM and make direct measurements of glucose metabolism in adults with prediabetes or T2DM. We 74 hypothesize that oral carnosine supplementation for 14 weeks would improve glucose metabolism and 75 reduce insulin levels in patients with prediabetes or T2DM compared to placebo. A recent systematic 76 review and meta-analysis of 20 studies determined that b-alanine, a precursor to carnosine, had no effect 77 78 on body composition in athletes ²³, however it is unknown whether it has any effect in patients with cardiometabolic disease. In our trial, we aim to utilize DXA to further elucidate the effect of carnosine 79 supplementation on whole body mass, fat percentage, fat mass and fat free mass in group of individuals 80 with overweight but not obese. 81

82 Methods:

83 Study design:

The study was a parallel-group double-blinded randomized control trial (RCT). Informed written consent was provided by all participants before commencing the trial. The trial was registered at clinicaltrials.gov (NCT02917928), and was conducted according to the Standardized Protocol Interventions: Recommendations for Interventional trials²⁴ and followed the CONSORT guidelines²⁵. The study was approved by Monash Health ethics committee (Ref: 16061A). and conforms to the Declaration of Helsinki²⁶.

90

92 Sample size:

93 The sample size of the study was calculated using the G-Power software, with blood glucose 94 concentrations via oral glucose tolerance test as the primary outcome. Data from a sub-study in this trial on subjects with overweight or obesity²⁷, and our trial in a cohort of participants with overweight or 95 obesity¹⁶, and from a study of subjects with diabetes by our group(ref); who had mean HbA1c of 7 and 96 fasting glucose of 10 was considered in the calculation. A sample size of 22 in each arm was required 97 to detect a 20% change in fasting glucose and absolute change of 0.5 in HBA1c for 80% power, with 98 target recruitment set to 50 participants based on a type I error of 0.05 (two-tailed)²⁸. A 20% change in 99 insulin sensitivity was selected based on evidence of similar improvement in insulin sensitivity when 100 treated with troglitazone, an hypoglycemic medication and insulin sensitiser²⁷. 101

102 *Study population:*

103 To be eligible, participants were required to be aged 18-70 years. All participants had pre-diabetes or 104 T2DM diagnosed by OGTT (according to the WHO guidelines) and were untreated, or taking only metformin. Participants were excluded if their HbA1c was 8% or higher or had changed their 105 medications in the past 3 months. Participants had to have BMI less than 40 kg/m² and a stable body 106 weight (no more than 5kg above or below the current weight over the last 12 months). Participants were 107 108 otherwise without diagnosis of any renal, cardiovascular, hematological, respiratory, gastrointestinal, or central nervous system disease, and not pregnant or lactating. Participants were not required to 109 110 change their diets or routine physical activity but were not included if they consumed more than 4 standard drinks per week for men and 2 standard drinks per week for women or if they smoked. 111 Recruited participants were required to remain on the same medications during the 14-week trial. The 112 participant would be discontinued from the study if their HbA1c became greater than 8% and a 113 114 medication change was stipulated by their medical practitioner at any stage of the study.

115 Recruitment, Intervention and Randomization

Participants were recruited through advertising via poster, radio, email newsletters and newspapers. 116 117 Interested participants were first contacted via phone and completed a screening eligibility questionnaire. Potentially eligible participants were then invited for a screening visit, where they were 118 assessed against the inclusion and exclusion criteria, underwent anthropometry and a screening OGTT 119 120 test at the Clinical Trials Centre of the Monash Health Translational Research Precinct. Eligible participants were randomized to intervention or placebo; the randomization used block sizes of 4 by 121 sex, using computer-generated randomization codes sent to the clinical trials pharmacy by the study 122 statistician. The carnosine group were asked to take 2g of carnosine (Flamma Group, 1g twice daily 123 including the study days) and the placebo group received an equivalent amount of methylcellulose (1g 124 twice daily) for 14 weeks. Medication was dispensed in indistinguishable capsules and containers to 125 126 ensure participants and researchers were blinded to the group allocation. Participants were asked to 127 inform the trial doctor of any adverse events as they arose and the trial doctor followed up with all participants at the end of the trial to discuss these. Participants were asked to return the treatment 128 containers at the end of the study to assess treatment compliance. Compliance was evaluated by 129 130 counting number of unconsumed capsules and dividing by number of capsules provided.

131 Outcomes:

The primary outcome was plasma glucose level on 2-hour oral glucose tolerance test (OGTT).
Secondary measures included HbA1c, insulin levels, body composition, calf muscle density, and
anthropometric parameters. All outcomes were measured at baseline and repeated after 14-weeks of
intervention.

136 Anthropometric, biochemical and body composition assessment

The study physician collected participants' medical history in person and performed a physical examination. This included collecting anthropometric data using a digital scale (Tanita BWB-600) and standing stadiometer, and vital signs collected via Omron digital blood pressure monitor (Model: BBP-742). Waist and hip measurements were measured using a measuring tape at the midpoint between the

141 upper iliac crest and the lowest rib, and at the widest part of the buttocks. Participants' bloods were 142 collected after an overnight fast of at least 10 hours using aseptic methods, and analyzed by the National 143 Association of Testing Authorities accredited Monash Health pathology service, which operates an 144 automated core laboratory at Monash Medical Centre Clayton.

- Whole-body dual-energy x-ray absorptiometry (DXA; Hologic Discovery A, Hologic, USA) was used to estimate fat and lean mass. The DXA scanner was calibrated daily with the manufacturer's spine phantom and the short-term intra-individual coefficient of variation (CV) for lean and fat mass was 1.60% and 2.67%, respectively. All DXA scans were analyzed by the same investigator.
- A single 2.5 mm transverse peripheral quantitative computed tomography (pQCT) scan (Stratec 149 150 XCT3000, Stratec Medizintechnik GmbH, Pforzheim, Germany) at a speed of 20 mm/s and voxel size of 0.8 mm was obtained at 66% of the tibial length of the non-dominant leg. The length of the tibia was 151 determined by measuring the distance between the prominence of the medial malleolus and the tibial 152 plateau. A planar scout view of the distal tibia was used to locate scan sites, and reference lines were 153 154 placed parallel to the distal joint surface of the tibia. Calf muscle density (mg/cm³; density of tissue within the muscle compartment after removal of subcutaneous fat and bone) was estimated using 155 manufacturer's algorithms and software (version 6.2). Scans were analyzed using a smoothing filter 156 (F03F05) at a threshold of 41 mg/cm³. The device was calibrated daily using the manufacturer's 157 phantom and the short-term intra-individual CV for muscle density was 1.2%. All pQCT scans were 158 analyzed by one individual. Adverse events while participating in the 14-week intervention period were 159 160 recorded in the progress notes as they arose and were reviewed with the chief investigator at the start 161 of every year while preparing the trial progress reports.

162 *Glucose and insulin assessment*

Participants completed a 2-hour OGTT following overnight fasting. The OGTT drink containing 75g
of glucose was consumed within 5 minutes after which bloods were collected aseptically into tubes
(Serum Separation Tubes – SST II) at 30-minute intervals (0, 30, 60, 90, 120 mins). After centrifugation,

166 the serum samples were stored at -80°C until analysis. Serum samples at all the time points were 167 measured for glucose and insulin, with the values also used to calculate the area under the curve (AUC) 168 by the trapezoidal method. The homeostatic model assessment of HOMA-IR (insulin resistance), 169 HOMA- β (steady state β -cell function %) and HOMA-S% (Insulin sensitivity) were also calculated as 170 described previously^{16,28,29}.

171 Statistical Analysis

Statistical analysis was performed with the statistical softwares JASP (v0.16.3), and SPSS (v29.0.0.). 172 173 Parametric data were reported as mean and standard deviations and non-parametric data were reported as median and interquartile range. Skew was assessed by Shapiro-Wilk testing, with skewed data 174 logarithmically transformed with satisfactory transformation assessed by evaluation of residual plots. 175 Continuous variables were analyzed using Analysis of Covariance (ANCOVA) adjusted for baseline 176 177 values. Additional ANCOVA was performed with diabetes (prediabetes vs T2DM) status, obesity status (BMI > 30) or metformin intake as covariates to evaluate interaction effects. All tests were two-tailed, 178 and alpha level of significance was set at 0.05. The primary analysis was performed on a complete case 179 protocol; however, an additional sensitivity analysis was performed with multiple imputation on 180 181 missing cases was performed. Missing data was imputed with predictive mean matching, with a total of five imputations modelled. The resulting data sets were analyzed as above, with the pooled mean and 182 standard error of the imputations, and the range of the resulting p-values reported. 183

184 <u>Results:</u>

A total of 88 participants were assessed for eligibility, with 49 eligible for enrolment and randomization. A total of 43 participants (13 women years and 30 men completed the trial at 14 weeks (23 placebo and 20 carnosine). Of 43, 22 participants were assessed as pre-diabetic and 21 as diabetic based on their screening OGTT. Five participants were lost to follow-up (Two placebo, three carnosine), and one additional participant was withdrawn after initiating treatment with an additional medication following randomization (Figure 1). Baseline participant data is presented in table 1.

191 Effect of carnosine supplementation on obesity measures

After the 14-week intervention, we detected a decrease in BMI of 0.74 kg/m² (p=0.048) in the carnosine group compared to placebo; but this did not remain significant when adjusting for diabetes status, obesity status or by metformin intake, and did not show any interaction effects with these variables. There were no differences in body weight, waist circumference or waist-to-hip ratio, body fat percentage (BF%), fat mass and fat free mass between the groups (all p>0.05) (Table 2. There were no interaction effects with diabetes status, obesity status or by metformin intake.

198 Effect of carnosine supplementation on glycemic measures

Carnosine supplementation reduced glucose levels at 90-minutes (-1.60 mmol/L, p=0.018) and 120minutes (-1.40 mmol/L, p=0.016), as well as glucose AUC (-3.30 mmol/L, p= 0.04) compared to placebo controls (Table 2, Figure 2). There were no changes in any other glucose or insulin measures, insulin AUC, HOMA-S, HOMA-β or HOMA-IR (all p>0.05) (table 2). There was no interaction between changes in any of the variables and diabetic status, obesity status or by metformin intake. The glucose results remained consistent in sensitivity analysis evaluating the effect of missing data imputation (Table 3).

Carnosine supplementation did not result in any adverse events, with the only reported adverse event being pain and mild bruising at the site of venipuncture in one participant. Overall, compliance was excellent (100%) with all participants consuming all capsules given to them.

209 Discussion:

In our randomized controlled study, we showed that carnosine supplementation for 14 weeks reduced 90 and 120-minute glucose levels after OGTT, and reduced glucose AUC. There were otherwise no significant changes to body composition, nor other glucometabolic measures. Given carnosine is safe, cost effective³⁰, and available over the counter in most countries, the reductions in glucose levels make carnosine an attractive agent for the management of prediabetes and diabetes, and warrants further large-scale trials to evaluate its long-term effects in the prevention and treatment of T2DM.

In this trial, the reduction of 3.3 mmol/L in glucose AUC following a OGTT represents a 7.2% decrease 216 217 in glucose response, which is likely to provide clinically significant outcomes in both preventing transition from prediabetes and in diabetic complications, particularly given 40% of the cohort was 218 219 already using metformin³¹. In the Diabetes Prevention Program Outcomes Study (DPPOS), participants 220 with prediabetes who returned to normoglycemia had 56% lower risk of diabetes than those who remained prediabetic³². Similarly, our recent meta-analysis pooling 23 interventional studies showed 221 improvement in glycemic control for participants with both type 1 and T2DM, following carnosine 222 223 supplementation leading to improvement of fasting glucose (mean difference (MD) [95% CI]= -0.6 224 mmol/L [-1.1, -0.1], p=0.03 and HbA1c (MD [95% CI]= -0.5% [-0.4, -0.6], p<0.001) ³³. In the meta-225 analysis, sensitivity analyses eliminating studies in which fasting glucose was elevated at baseline, still 226 favored supplementation with carnosine³³, aligning with the results from the present study. We and others also highlighted that there was insufficient data to evaluate whether carnosine supplementation 227 improved glucose following OGTT^{33,34}, although some showed glucose lowering effects in people with 228 229 diabetes ¹⁷. While our findings of improved glucose control after OGTT align with these findings, our study did not show changes in HbA1c levels or fasting glucose ^{35,36}. This is potentially due to differences 230 in participants, with our study investigating people with pre-diabetes and relatively well-controlled 231 T2DM. Additionally, the 14-week intervention in this study may have been too short to cause an 232 233 appreciable change in HbA1c, which typically requires longer to decrease. While the evidence provided 234 in this study has demonstrated an effect of carnosine supplementation on glucose concentrations, the 235 mechanisms underpinning this are unclear. The glucose-lowering effect was in the absence of an alteration in insulin concentrations, as well as indirect measures of insulin sensitivity, which further 236 237 highlighted the differences in baseline insulin levels between the placebo and treatment groups (2.7 238 mIU/ml vs 4.1mIU/ml); is a possible reason as to why a significant change in insulin at 14 weeks was not detected. This may indicate decreased hepatic glucose output a potential mediator of the effect seen 239 in this trial. 240

Carnosine is rapidly hydrolyzed by serum carnosinase to its constituents b-alanine and histidine.Carnosine's poor bioavilaibility in humans is highlighted by the fact that individuals with CNDP1

genotype characteristed by low serum carnosinase activity are often afflicted by carnosinemia³⁷,
however carnosinemia can be induced by intake³⁷. The high variation in serum carnosinase activity
seems a natural variation and depends upon the polymorphism of the CNDP1 genotype inherited.

Although our study found a decrease of 0.74 kg/m² in BMI in the carnosine group (p=0.045) after 14-246 247 week supplementation compared to the placebo; with no significant change in weight between followup and baseline, this is unlikely to be clinically relevant, and is potentially random. Our study found no 248 change in waist circumference or waist-to-hip ratio after carnosine supplementation, in line with 249 previous studies of similar cohorts^{16,23}. Liu et al³⁶ reported in one trial that carnosine as part of a 250 combined supplement with cinnamon and chromium increased lean mass, which is in contrast to our 251 trial. Although, our study cohort was largely overweight rather than obese and several participants had 252 253 been pretreated with metformin and/or diet control and exercise, which could explain the lack of effect observed in these measures. Another meta-analysis³³, also found a significant 3.5cm decrease in waist 254 circumference, findings not seen here. A prior RCT³⁸ compared β -alanine (BA) supplementation only 255 (n=8) (the rate-limiting precursor to carnosine and a preferred method to increase muscle carnosine 256 257 levels by circumventing serum carnosinase activity), creatine only (n=8) and BA plus creatine (n=7) or placebo (n=7) for 28 days along with a structured exercise routine in a group of physically active 258 259 females³⁸. They found that despite addition of exercise, there were no reductions in body weight, fat mass, body fat and fat-free mass³⁸ in any cohort; findings echoed in another trial of β -alanine and 260 exercise combined³⁹. Another recent meta-analysis of 426 participants found no effect of 261 supplementation on any measure of body composition, and no interaction effects resulting from 262 resistance training, endurance training or combined training ²³. This data, and ours provides evidence 263 that neither carnosine nor β -alanine supplementation seems to affect body composition directly, with or 264 without complimentary exercise in adults without obesity. However, it should be noted that most of 265 266 these studies were in athletes who are less likely to show large changes in body composition. Further trials which supplement carnosine in individuals with obesity may better elucidate an effect of carnosine 267 on body composition. 268

269 The findings of the current study agree with previous work demonstrating that carnosine has glucose-270 lowering effects in individuals with impaired glucose tolerance, however, our data was unable to demonstrate any changes in insulin levels as found in other similar trials^{16,40}, possibly due to the large 271 number of participants with diabetes being treated with metformin in our cohorts or the fact that we 272 273 used indirect measurements for insulin sensitivity and secretion. We have shown previously that 274 carnosine supplementation leads to increases in insulin sensitivity and secretion in individuals with overweight and obesity¹⁶. Future studies will need to employ gold-standard euglycemic-275 hyperinsulinemic clamp and intravenous glucose tolerance test to accurately evaluate carnosine's effect 276 on these measures. 277

Chronic inflammation, oxidative stress and advanced glycation end products (AGE) and advanced lipid 278 279 peroxidation end products (ALE) have all been implicated in the pathogenesis of diabetes and its complications ^{41,42}. Carnosine is thought to improve glycemic control at least in part via anti-AGE action 280 by preventing the formation of cross-linked proteins by methylglyoxal (MG) and neutralizing it^{43,44}. 281 Free sugars undergo a series of biochemical changes⁴⁵ resulting in their oxidization after which they 282 283 covalently bond to proteins²⁵. These modified proteins form permanent cross-linkages with oxidized sugars and other proteins over time to form AGEs, which through activation of immune processes, 284 contribute to worsening hyperglycaemia^{46,47}. Carnosine has been proposed to improve a range of 285 cardiovascular, dyslipidemic, and inflammatory outcomes 15,17,48 – all essential for the care of patients 286 287 with diabetes. This adds additional benefits to the use of carnosine as a part of treatment of T2DM, particularly in the light of the glucose lowering effect demonstrated here. The analysis of inflammatory 288 289 and lipid profiles collected as part of this trial is currently being analysed and will be reported in another 290 article.

291 Strengths, Limitations, and future direction

292 While this study was methodologically robust, there are some limitations We used surrogate measures 293 of insulin sensitivity and secretion HOMA-IR HOMA-S and HOMA- β which are not as sensitive as the 294 gold-standard methods. Our analysis showed that the baseline insulin level for the carnosine group was

295 29.8% higher than the baseline insulin for the placebo group. This random characteristic as well as 296 missing OGTT and insulin data for a few participants (table 2) may have further obscured the detection of a significant change in insulin levels after 14 weeks, even though the carnosine group lowered 297 HOMA-IR scores to greater degree than the placebo group (change of -1.4 mIU/ml vs -0.18 mIU/ml), 298 299 although these results were not stastically significant. The higher insulin level in the carnosine group at baseline may have been a reason why a larger therapeutic change was evident after treatment. Moreover, 300 the trial was limited by a smaller sample size due to the difficulty in recruiting participants with 301 prediabetes and T2DM treated with metformin only and furthermore by COVID-19 pandemic which 302 halted the trial for several months. Another limitation was the relatively short follow-up period, which 303 left questions surrounding treatment durability unanswered. 304

305 Conclusion

A 14-week regimen of carnosine supplementation reduced glucose concentrations following OGTT in patients with prediabetes and diabetes but had no effect on insulin concentrations or obesity measures. While this makes carnosine a promising candidate in the management of T2DM, further randomized controlled trials of carnosine supplementation for cardiometabolic conditions are warranted, particularly in the light of carnosine's additional protective benefits to cardiovascular and inflammatory outcomes relevant to diabetes^{33,49}.

312 Acknowledgements

We acknowledge Flamma Group for providing carnosine for the trial and Ms. Josphine Johnson, Dr.
Estifanos Baye, Ms Paula Fudge-Larsen and Dr. Martin Schonn for their assistance with data collection.
We also acknowledge funding agencies including CASS and Royal Australasian College of Physicians
foundations. Also, we thank volunteers Dr. Aylin Hilberath, Dr. Dilek Tuncel, Dr. Lachlan B McMillan
and Dr. Mavil May Cervo for their assistance.

318 Conflicts of Interest:

319 The authors report no conflicts of interest.

medRxiv preprint doi: https://doi.org/10.1101/2023.03.18.23287432; this version posted March 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

321 References

322 323 1. Lin X, Xu Y, Pan X, et al. Global, regional, and national burden and trend of diabetes in 195 324 countries and territories: an analysis from 1990 to 2025. Scientific Reports. 325 2020;10(1):14790. 326 2. Cho NH, Shaw J, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes 327 prevalence for 2017 and projections for 2045. Diabetes research and clinical practice. 328 2018;138:271-281. 329 3. Li J, Tong Y, Zhang Y, et al. Effects on All-cause Mortality and Cardiovascular Outcomes in 330 Patients With Type 2 Diabetes by Comparing Insulin With Oral Hypoglycemic Agent Therapy: 331 A Meta-analysis of Randomized Controlled Trials. Clinical Therapeutics. 2016;38(2):372-332 386.e376. 333 4. Liu J, Ren Z-H, Qiang H, et al. Trends in the incidence of diabetes mellitus: results from the Global Burden of Disease Study 2017 and implications for diabetes mellitus prevention. BMC 334 Public Health. 2020;20(1):1415. 335 336 5. Williams R, Karuranga S, Malanda B, et al. Global and regional estimates and projections of 337 diabetes-related health expenditure: Results from the International Diabetes Federation 338 Diabetes Atlas, 9th edition. Diabetes Research and Clinical Practice. 2020;162. 339 6. van den Arend IJM, Stolk RP, Krans HMJ, Grobbee DE, Schrijvers AJP. Management of type 2 340 diabetes: a challenge for patient and physician. Patient Education and Counseling. 341 2000;40(2):187-194. 342 7. Cetin M, Sahin S. Microparticulate and nanoparticulate drug delivery systems for metformin 343 hydrochloride. Drug Delivery. 2016;23(8):2796-2805. 344 8. McCoy RG, Dykhoff HJ, Sangaralingham L, et al. Adoption of new glucose-lowering 345 medications in the US—the case of SGLT2 inhibitors: nationwide cohort study. 346 2019;21(12):702-712. 347 9. Nauck MA, Wefers J, Meier JJJTLD, Endocrinology. Treatment of type 2 diabetes: challenges, 348 hopes, and anticipated successes. 2021;9(8):525-544. 349 Crush K. Carnosine and related substances in animal tissues. Comparative biochemistry and 10. 350 physiology. 1970;34(1):3-30. 351 Kohen R, Yamamoto Y, Cundy KC, Ames BN. Antioxidant activity of carnosine, 11. 352 homocarnosine, and anserine present in muscle and brain. Proceedings of the National 353 Academy of Sciences. 1988;85(9):3175-3179. 354 12. Peters V, Klessens CQF, Baelde HJ, et al. Intrinsic carnosine metabolism in the human kidney. 355 Amino Acids. 2015;47(12):2541-2550. 356 Matthews JJ, Artioli GG, Turner MD, Sale C. The physiological roles of carnosine and β -13. 357 alanine in exercising human skeletal muscle. Medicine & Science in Sports & Exercise. 358 2019;51(10):2098-2108. 359 14. Baye E, Ukropcova B, Ukropec J, Hipkiss A, Aldini G, de Courten B. Physiological and therapeutic effects of carnosine on cardiometabolic risk and disease. Amino Acids. 360 361 2016;48(5):1131-1149. 362 15. Feehan J, Hariharan R, Buckenham T, et al. Carnosine as a potential therapeutic for the management of peripheral vascular disease. 2022. 363 364 16. de Courten B, Jakubova M, de Courten MP, et al. Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial. Obesity. 2016;24(5):1027-1034. 365 366 17. Houjeghani S, Kheirouri S, Faraji E, Jafarabadi MA. I-Carnosine supplementation attenuated 367 fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor– α

		It is made available under a CC-BY-NC-ND 4.0 International license .
368		levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical
369	10	trial. Nutrition Research. 2018;49:96-106.
3/0	18.	Elbarbary NS, Ismail EAR, El-Naggar AR, Hamouda MH, El-Hamamsy M. The effect of 12
3/1		weeks carnosine supplementation on renal functional integrity and oxidative stress in
3/2		Dispetes 2018:10(2):470.477
3/3 274	10	Diubeles. 2018;19(3):470-477.
574 275	19.	on exercise capacity and insulin consitivity in individuals with type 2 diabetes mollitus: a
375		randomised double-blind and placebo-controlled pilot trial / Nutr Sci Res 2016:1(3):1-7
370	20	Baye F. Likronec I. de Courten MPI, et al. Effect of carnosine supplementation on the plasma
378	20.	linidome in overweight and obese adults: a nilot randomised controlled trial. <i>Scientific</i>
379		Reports 2017.7(1):17458
380	21.	Frion DM. Park HI, Lee HY. The role of lipids in the pathogenesis and treatment of type 2
381		diabetes and associated co-morbidities. <i>BMB Rep.</i> 2016;49(3):139-148.
382	22.	Parhofer KG. Interaction between Glucose and Lipid Metabolism: More than Diabetic
383		Dyslipidemia. <i>Diabetes Metab J.</i> 2015;39(5):353-362.
384	23.	Ashtary-Larky D, Bagheri R, Ghanavati M, et al. Effects of beta-alanine supplementation on
385		body composition: a GRADE-assessed systematic review and meta-analysis. Journal of the
386		International Society of Sports Nutrition. 2022;19(1):196-218.
387	24.	Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration:
388		guidance for protocols of clinical trials. <i>Bmj.</i> 2013;346.
389	25.	Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: Updated Guidelines for
390		Reporting Parallel Group Randomized Trials. Annals of Internal Medicine. 2010;152(11):726-
391		732.
392	26.	World Medical Association Declaration of Helsinki: ethical principles for medical research
393		involving human subjects. Jama. 2013;310(20):2191-2194.
394	27.	Menon K, Cameron JD, de Courten M, de Courten B. Use of carnosine in the prevention of
395		cardiometabolic risk factors in overweight and obese individuals: study protocol for a
396		randomised, double-blind placebo-controlled trial. <i>BMJ open</i> . 2021;11(5):e043680-e043680.
397	28.	Baye E, Menon K, de Courten MPJ, Earnest A, Cameron J, de Courten B. Does
398		supplementation with carnosine improve cardiometabolic health and cognitive function in
399		patients with pre-diabetes and type 2 diabetes? study protocol for a randomised, double-
400	20	blind, placebo-controlled trial. <i>BIVIJ Open.</i> 2017;7(9):e017691.
401	29.	matchews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis
402		inculin concontrations in man. Diabatologia, 1985;29(7):412,410
405	20	Manan K. da Caurtan P. Magliana DI. Adami 7. Liow D. Zamar F. The Cast Effectiveness of
404	50.	Supplemental Carposing in Type 2 Diabetes Nutrients 2022:14(1):215
405	31	Riedel AA Heien H. Wogen I. Plauschinat CA Loss of Glycemic Control in Patients with Type
400	51.	2 Diabetes Mellitus Who Were Receiving Initial Metformin, Sulfonylurea, or
408		Thiazolidinedione Monotherapy. Pharmacotherapy: The Journal of Human Pharmacology
409		and Drug Therapy, 2007:27(8):1102-1110.
410	32.	Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF. Kahn SE. Effect of regression from
411		prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results

- 412 from the Diabetes Prevention Program Outcomes Study. *The Lancet.* 2012;379(9833):2243413 2251.
 414 33. Menon K, Marquina C, Liew D, Mousa A, de Courten B. Histidine-containing dipeptides
- 414 55. Interiori K, Interquina C, Liew D, Mousa A, de Courten B. Histidine-containing dipeptides
 415 reduce central obesity and improve glycaemic outcomes: A systematic review and meta 416 analysis of randomized controlled trials. *Obesity Reviews.* 2020;21(3):e12975.

medRxiv preprint doi: https://doi.org/10.1101/2023.03.18.23287432; this version posted March 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

	porpotatty.	
It is made available under a	CC-BY-NC-ND 4.0	International license .

417 418 410	34.	Matthews JJ, Dolan E, Swinton PA, et al. Effect of Carnosine or β -Alanine Supplementation on Markers of Glycemic Control and Insulin Resistance in Humans and Animals: A Systematic
419	35	Elbarbary NS Ismail EAR El-Naggar AR Hamouda MH El-Hamamsy M The effect of 12
420	55.	weeks carnosine supplementation on renal functional integrity and oxidative stress in
422		pediatric patients with diabetic penhropathy: a randomized placebo-controlled trial
423		Pediatric Diabetes, 2018:19(3):470-477.
424	36	Liu Y Cotillard A Vatier C et al Correction: A Dietary Supplement Containing Cinnamon
425	50.	Chromium and Carnosine Decreases Fasting Plasma Glucose and Increases Lean Mass in
426		Overweight or Obese Pre-Diabetic Subjects: A Randomized, Placebo-Controlled Trial, <i>Plas</i>
427		one. 2015:10(12):e0145315.
428	37.	Everaert I. Taes Y. Heer ED. et al. Low plasma carnosinase activity promotes carnosinemia
429		after carnosine ingestion in humans. American Journal of Physiology-Renal Physiology.
430		2012:302(12):F1537-F1544.
431	38.	Kresta JY. Oliver JM. Jagim AR. et al. Effects of 28 days of beta-alanine and creatine
432		supplementation on muscle carnosine, body composition and exercise performance in
433		recreationally active females. Journal of the International Society of Sports Nutrition.
434		2014;11(1):55.
435	39.	Kendrick IP, Harris RC, Kim HJ, et al. The effects of 10 weeks of resistance training combined
436		with β -alanine supplementation on whole body strength, force production, muscular
437		endurance and body composition. Amino Acids. 2008;34(4):547-554.
438	40.	Regazzoni L, de Courten B, Garzon D, et al. A carnosine intervention study in overweight
439		human volunteers: bioavailability and reactive carbonyl species sequestering effect.
440		Scientific reports. 2016;6:27224.
441	41.	Meerwaldt R, Links T, Zeebregts C, Tio R, Hillebrands J-L, Smit A. The clinical relevance of
442		assessing advanced glycation endproducts accumulation in diabetes. Cardiovascular
443		Diabetology. 2008;7(1):29.
444	42.	de Courten B, de Courten MP, Soldatos G, et al. Diet low in advanced glycation end products
445		increases insulin sensitivity in healthy overweight individuals: a double-blind, randomized,
446		crossover trial. Am J Clin Nutr. 2016;103(6):1426-1433.
447	43.	Reddy VP, Garrett MR, Perry G, Smith MA. Carnosine: A Versatile Antioxidant and
448		Antiglycating Agent. Science of Aging Knowledge Environment. 2005;2005(18):pe12-pe12.
449	44.	Hipkiss AR, Chana H. Carnosine Protects Proteins against Methylglyoxal-Mediated
450		Modifications. Biochemical and Biophysical Research Communications. 1998;248(1):28-32.
451	45.	Maillard LC. Action des acides amines sur les sucres: formation des melanoidines par voie
452	10	methodique. <i>CR Acad Sci.</i> 1912;154:66-68.
453	46.	Hobart LJ, Seibel I, Yeargans GS, Seidler NW. Anti-crosslinking properties of carnosine:
454	47	Significance of histidine. Life Sciences. 2004;75(11):1379-1389.
455	47.	Browniee M, Pongor S, Cerami A. Covalent attachment of soluble proteins by
450		The lowred of experimental medicine, 1082:158/5/1720, 1744
457	10	The Journal of experimental medicine. 1983;138(5):1739-1744.
458	48.	lipidama in every weight and choice adulte: a pilot randomiced controlled trial 2017;7(1):1.7
455	٨٥	Menon K Marquina C Hoi P Liew D Mouse A de Courten B Carposine and histidine
400	49.	containing dipentides improve dyslipidemia: a systematic review and meta-analysis of
401		randomized controlled trials Nutrition Reviews 2020.78(11).020-051
702		
463		
464		

medRxiv preprint doi: https://doi.org/10.1101/2023.03.18.23287432; this version posted March 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a C	C-BY-NC-ND 4.0 International license .
It is made available under a C	JC-BY-NC-ND 4.0 International license .

466	
467	
468	
469	
470	
471	
472	
473	
474	
475	
476	
477	
478	
479	
480	
481	
482	
483	Figure legends:
484	Figure 1: Study flow diagram
485	Figure 2: Glucose levels after oral glucose tolerance test at baseline and after 14-week intervention
486	by intervention group.



487

488 **Figure 1:** Study flow diagram

489 Figure 2:: Glucose levels (A) and Insulin level (B) after oral glucose tolerance test at baseline and after 14-week intervention by intervention group.





496 Figure 3: Glucose response after OGTT per participant. Bars denote Mean and SD.



499 Table 1: Baseline characteristics of participants

	Placebo (n=23)		Carnosine (n=20)	
Age – years, (median [IOR])	52 [28.4	- 65.3]	53.8 [30	.1 – 66.3]
$\frac{(\text{Intural } [1QK])}{\text{Female } (n [\%])}$	7 [3	0%1	6[3	30%1
Pre-	11	/12	1	1/9
diabetic/Diabeti	11/	12	1	
c				
Treated with	Ģ)		8
Metformin				
	Mean	SD	Mean	SD
Weight (kg)	81.8	14.5	88.4	23.8
Height (cm)	169.0	10.3	172.3	12.3
Waist	99.0	8.8	103.3	14.7
Circumference				
(cm)	102.5	7.0	105 7	1.5.1
Нр	102.5	7.9	105.7	15.1
(om)				
Glucose - Omins	6.4	11	6.4	11
(mmol/L)	0.1	1.1	0.1	1.1
Glucose -	e - 9.6 1.3		10.3	2.3
30mins				
(mmol/L)	mmol/L)			
Glucose -	12.1	2.1	13.0	2.4
60mins				
(mmol/L)				
Glucose -	12.3	2.7	13.3	3.5
90mins				
(mmol/L)	11.0	2.0	12.0	2.5
Glucose -	11.9	5.0	12.0	5.5
(mmol/L)				
Glucose AUC	43.2 7.5		45.8	9,792
Insulin - 0 mins	9.7	5.7	14.6	19.3
(mIU/ml)				
Insulin - 30	32.7	30.3	34.4	17.3
mins (mIU/ml)				
Insulin - 60	41.8	26.9	67.5	58.0
mins (mIU/ml)	mins (mIU/ml)			
Insulin - 90 56.1 42		42.3	96.5	92.0
mins (mIU/ml)	nins (mIU/ml)		104.0	111.0
Insulin - 120	70.9	64.5	104.0	111.8
mins (miU/ml)	150.1	112.2	257 5	216.6
	139.1 67	113.3	<u> </u>	<u> </u>
HOMA ID	2.7	1 7	<u> </u>	53
	51.7	37.6	61 4	101.8
IIOMA-5	51.7	57.0	01.4	101.0

	ΗΟΜΑ- β	80.8	63.6	118.8	173.3
500					
501					
502					
503					
504					
505					
506					
507					
508					
509					
510					
511					
512					
513					
514					
515					
516					
517					
518					
519					
520					
521					
522					
523					
524					
525					
526					
527					
528					
529					
530					

		Baseline±S	Follow-	Baseline±S	Follow-Up±SD	Between group	Between group p-	
		D	up±SD	D		mean change*	value	
	Weight(kg)	81.8±14.5	81.5±14.7	88.4±23.8	88.7±24.3	0.012	0.6	
	BMI (kg/m ²)	28.5 ± 3.7	28.4±3.6	29.8±4.9	30.2±4.8	-0.74	0.048	
Table	Waist 2: Baseline and follow-	99.0±8.8 up values and c	96.87±7.8 hanges in anthr	103.3±14.7 opometric, bod	103.8±16.0 y composition and metabol	-1.59 ic measures after 14	0.2 weeks of supplementat	ion
+ n=25	· Placebo(fm)(3) & Car	mosine(n=12)	*Mean change	in Carnosine or	un – Mean change in Plac	eho		
BMI (1	Waist to hip ratio	1A ⁰ 1877881960s	tatic model ass	essment = insuli	n resistance ^{7±} HOMA-S%	homeostatic model a	ssessment ^{0.6} insulin sec	retion): HOMA-
ß (hon	eostatic WHR assessm	ent – beta cell f	function): AUC	(area under the	curve). All analysis betwe	en group were also a	diusted for diabetic sta	tus, obesity
status,	metfeat masse (kg)e and	$sex^{28.5\pm7.0}$	28.0±7.26	33.4±11.7	32.8±10.9	-0.47	0.3	
,	Body fat (%)	35.6±6.7	35.13±6.9	37.01±7.9	36.8±7.6	-0.31	0.4	
	Fat free mass (kg)	51.8±11.7	51.9±11.7	53.1±13.8	53.2±12.7	-0.27	0.5	
	Calf muscle density	86.0 ± 2.9	85.5±4.0	86.3±5.04	86.2±5.04	-0.74	0.2	
	(mg/cm ³) †							
	Glucose - 0 minutes	6.4±1.1	6.3±1.2	6.4±1.1	6.2±1.3	0.08	0.7	
	(mmol/L)							
	Glucose -30	9.6±1.3	9.6±2.2	10.3 ± 2.3	10.2 ± 2.3	0.02	1.0	
	minutes (mmol/L)							
	Glucose -60	12.1 ± 2.1	11.6±2.7	13.0±2.4	12.1 ± 2.7	0.42	0.5	
	minutes (mmol/L)							
	Glucose - 90	12.3 ± 2.7	12.2±2.9	13.3±3.5	11.7 ± 3.05	1.31	0.02	
	minutes (mmol/L)							
	Glucose - 120	11.9 ± 3.0	11.9 ± 3.0	12.0±3.5	10.6 ± 4.1	1.60	0.02	
	minutes (mmol/L)							
	Glucose AUC	43.2±7.5	43.03±9.4	45.8±9.8	42.4±9.9	3.19	0.04	
	Insulin - 0 minutes	9.7±5.7	9.1±4.6	14.6±19.3	10.3 ± 6.8	0.06	1.0	
	(mIU/ml)							
	Insulin - 30	32.7 ± 30.3	35.5±42.1	34.4±17.3	34.2±19.6	4.03	0.5	
	minutes (mIU/ml)							
	Insulin - 60	41.8 ± 26.9	42.6±30.9	67.5 ± 58.0	58.9±64.3	4.25	0.7	
	minutes (mIU/ml)							
	Insulin - 90	56.1±42.3	52.8±39.2	96.5±92.0	91.3±104.4	3.59	0.7	
	minutes (mIU/ml)							
	Insulin - 120	70.9 ± 64.5	62.6±42.8	104.0 ± 111.8	68.1 ± 65.0	13.9	0.1	
	minutes (mIU/ml)							
	Insulin AUC	159.1±2.7	165.1±123.	257.5±216.6	217.0±197.0	31.63	0.2	
			6			0.10	0.1	
	HbA1c (%)	6.7±0.8	6.72±1.14	6.5±0.6	6.7±1.1	-0.18	0.4	
	HOMA-IR	2.7±1.7	2.52±1.35	4.1±5.3	2.7±1.6	0.11	0.8	
	HOMA-S(%)	51.7±37.6	51.9±29.1	61.4±101.8	161.4±501.1	-116.2	0.3	
	ΗΟΜΑ- β	80.8±63.6	86.2±108.4	118.8±173.3	140.1±217.8	-26.2	0.7	

Variable	Pooled imputed	mean estimates (Std Error)	Range of imputed p-values
Glucose - 0 minutes	Placebo	6.23 (0.96)	0.19-0.97
(mmol/L)	Carnosine	6.21 (0.71)	
Glucose -30 minutes	Placebo	10.25 (0.63)	0.25-0.99
(mmol/L)	Carnosine	9.86 (0.55)	
Glucose -60 minutes	Placebo	11.90 (0.80)	0.18-0.88
(mmol/L)	Carnosine	11.66 (0.55)	
Glucose - 90 minutes	Placebo	12.69 (0.46)	0.010-0.018
(mmol/L)	Carnosine	11.31 (0.41)	
Glucose - 120 minutes	Placebo	12.05 (0.53)	0.010-0.023
(mmol/L)	Carnosine	10.56 (0.48)	
Glucose AUC	Placebo	44.06 (1.03)	0.024-0.055
	Carnosine	41.12 (1.05)	
Insulin - 0 minutes	Placebo	9.68 (1.12)	0.68-0.96
(mIU/ml)	Carnosine	9.80 (1.20)	
Insulin - 30 minutes	Placebo	33.52 (9.68)	0.08-0.76
(mIU/ml)	Carnosine	21.78 (13.68)	
Insulin - 60 minutes	Placebo	49.03 (9.65)	0.34-0.86
(mIU/ml)	Carnosine	45.69 (9.33)	
Insulin - 90 minutes	Placebo	63.82 (10.24)	0.18-0.81
(mIU/ml)	Carnosine	77.44 (11.55)	
Insulin - 120 minutes	Placebo	69.08 (7.94)	0.086-0.82
(mIU/ml)	Carnosine	63.15 (11.17)	
Insulin AUC	Placebo	185.32 (19.84)	0.42-0.99
	Carnosine	181.87 (21.61)	

Table 3: Sensitivity analysis of glucose and insulin results, through multiple imputation of missing results, and resulting ANCOVA. Five imputations were used with pooled

means and standard errors, and the resulting pvalue ranges provided.